Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 175 matching drugs for FGFR4 — including drugs targeting any of its 12 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR4 Direct 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR4 Direct 3
pembrolizumab, belzutifan, lenvatinib FGFR4 Direct 3
bbi-355, erlotinib, futibatinib FGFR4 Direct 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FGFR4 Direct 2
lenvatinib, pembrolizumab FGFR4 Direct 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FGFR4 Direct 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FGFR4 Direct 2
pembrolizumab, lenvatinib FGFR4 Direct 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FGFR4 Direct 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FGFR4 Direct 2
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging FGFR4 Direct 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography FGFR4 Direct 1
erdafitinib FGFR4 Direct yes 1
h101, tislelizumab, lenvatinib FGFR4 Direct 1
lenvatinib, bevacizumab FGFR4 Direct 1
paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) FGFR4 Direct 1
pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel FGFR4 Direct 1
pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel FGFR4 Direct 1
pemigatinib FGFR4 Direct 1
ponatinib FGFR4 Direct 1
serplulimab, lenvatinib, paclitaxel/paclitaxel-albumin/paclitaxel liposome FGFR4 Direct 1
tace, lenvatinib, combined with tislelizumab group FGFR4 Direct 1
tace, tislelizumab, lenvatinib FGFR4 Direct 1
nintedanib FGFR4 Direct yes 0
nintedanib esylate FGFR4 Direct yes 0
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FGFR1 SSL via FGFR1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FGFR2 SSL via FGFR2 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FGFR1 SSL via FGFR1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FGFR2 SSL via FGFR2 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR1 SSL via FGFR1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR2 SSL via FGFR2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SRC SSL via SRC 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR1 SSL via FGFR1 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR2 SSL via FGFR2 3
pembrolizumab, belzutifan, lenvatinib FGFR1 SSL via FGFR1 3
pembrolizumab, belzutifan, lenvatinib FGFR2 SSL via FGFR2 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FGFR1 SSL via FGFR1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FGFR2 SSL via FGFR2 2
bbi-355, erlotinib, futibatinib FGFR1 SSL via FGFR1 2
bbi-355, erlotinib, futibatinib FGFR2 SSL via FGFR2 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SRC SSL via SRC 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib FGFR1 SSL via FGFR1 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib FGFR2 SSL via FGFR2 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FGFR1 SSL via FGFR1 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FGFR2 SSL via FGFR2 2
lenvatinib, pembrolizumab FGFR1 SSL via FGFR1 2
lenvatinib, pembrolizumab FGFR2 SSL via FGFR2 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FGFR1 SSL via FGFR1 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FGFR2 SSL via FGFR2 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FGFR1 SSL via FGFR1 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FGFR2 SSL via FGFR2 2
nintedanib FGFR1 SSL via FGFR1 yes 2
nintedanib FGFR2 SSL via FGFR2 yes 2
nintedanib SRC SSL via SRC 2
nintedanib, pembrolizumab FGFR1 SSL via FGFR1 2
nintedanib, pembrolizumab FGFR2 SSL via FGFR2 2
nintedanib, pembrolizumab SRC SSL via SRC 2
pembrolizumab, lenvatinib FGFR1 SSL via FGFR1 2
pembrolizumab, lenvatinib FGFR2 SSL via FGFR2 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FGFR1 SSL via FGFR1 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FGFR2 SSL via FGFR2 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FGFR1 SSL via FGFR1 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FGFR2 SSL via FGFR2 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery FGFR1 SSL via FGFR1 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery FGFR2 SSL via FGFR2 2
regorafenib FGFR1 SSL via FGFR1 2
regorafenib FGFR2 SSL via FGFR2 yes 2
regorafenib, laboratory biomarker analysis FGFR1 SSL via FGFR1 2
regorafenib, laboratory biomarker analysis FGFR2 SSL via FGFR2 2
sorafenib, administered orally, ct/mri FGFR1 SSL via FGFR1 2
afatinib, dasatinib, palbociclib, everolimus, olaparib SRC SSL via SRC 1
atezolizumab, tivozanib FGFR1 SSL via FGFR1 1
atorvastatin, temozolomide, radiotherapy HMGCR SSL via HMGCR 1
bevacizumab, dasatinib, placebo SRC SSL via SRC 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging FGFR1 SSL via FGFR1 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging FGFR2 SSL via FGFR2 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography FGFR1 SSL via FGFR1 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography FGFR2 SSL via FGFR2 1
bosutinib SRC SSL via SRC yes 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab FGFR1 SSL via FGFR1 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab FGFR2 SSL via FGFR2 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab SRC SSL via SRC 1
cisplatin, pemetrexed disodium, sorafenib FGFR1 SSL via FGFR1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride SRC SSL via SRC 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method SRC SSL via SRC 1
dasatinib, laboratory biomarker analysis, physiologic testing SRC SSL via SRC 1
dasatinib, mfolfox6 SRC SSL via SRC 1
dasatinib, pharmacological study SRC SSL via SRC 1
dasatinib, temozolomide, placebo, radiation therapy SRC SSL via SRC 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) PIK3R1 SSL via PIK3R1 1
enzastaurin, lomustine PIK3R1 SSL via PIK3R1 1
enzastaurin, temozolomide, radiation therapy PIK3R1 SSL via PIK3R1 1
erdafitinib FGFR1 SSL via FGFR1 yes 1
erdafitinib FGFR2 SSL via FGFR2 yes 1
everolimus, sorafenib FGFR1 SSL via FGFR1 1
gemcitabine, erlotinib, sorafenib FGFR1 SSL via FGFR1 1
gemcitabine, placebo, sorafenib FGFR1 SSL via FGFR1 1
gemcitabine, sorafenib, radiotherapy FGFR1 SSL via FGFR1 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff FGFR1 SSL via FGFR1 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.